{"id":75097,"date":"2026-05-05T15:44:18","date_gmt":"2026-05-05T10:14:18","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=75097"},"modified":"2026-05-05T15:44:21","modified_gmt":"2026-05-05T10:14:21","slug":"ipca-laboratories-q4-results-2026-2","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/","title":{"rendered":"IPCA Laboratories Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook"},"content":{"rendered":"<p><strong>IPCA Laboratories<\/strong> Q4 results are expected on <strong>May 2026<\/strong>. Analyst consensus estimates revenue at Rs 1,850\u20132,050 Cr and PAT at Rs 195\u2013235 Cr for the January to March 2026 quarter. This article covers what analysts are expecting, five key growth factors to watch, risks to the investment thesis, and a complete FAQ section for investors.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here \u2014 Get Free SEBI-registered Research on IPCA Laboratories on Univest.<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#IPCA_Laboratories_Q4_FY26_Results_Overview\" title=\"IPCA Laboratories Q4 FY26 Results Overview\">IPCA Laboratories Q4 FY26 Results Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#What_to_Expect_from_IPCA_Laboratories_Q4_FY26\" title=\"What to Expect from IPCA Laboratories Q4 FY26\">What to Expect from IPCA Laboratories Q4 FY26<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#Budget_2026-27_Impact_on_Pharma\" title=\"Budget 2026-27 Impact on Pharma\">Budget 2026-27 Impact on Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#Q4_FY26_Estimates_Table\" title=\"Q4 FY26 Estimates Table\">Q4 FY26 Estimates Table<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#5_Key_Growth_Factors_to_Watch_in_IPCA_Laboratories_Q4_FY26_Results\" title=\"5 Key Growth Factors to Watch in IPCA Laboratories Q4 FY26 Results\">5 Key Growth Factors to Watch in IPCA Laboratories Q4 FY26 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#1_US_Generics_Revenue_and_Market_Share\" title=\"1. US Generics Revenue and Market Share\">1. US Generics Revenue and Market Share<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#2_Domestic_Branded_Formulations_Volume\" title=\"2. Domestic Branded Formulations Volume\">2. Domestic Branded Formulations Volume<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#3_API_Business_Margin_Recovery\" title=\"3. API Business Margin Recovery\">3. API Business Margin Recovery<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#4_FDA_Inspection_Status\" title=\"4. FDA Inspection Status\">4. FDA Inspection Status<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#5_R_D_Pipeline_and_ANDA_Filings\" title=\"5. R&amp;D Pipeline and ANDA Filings\">5. R&amp;D Pipeline and ANDA Filings<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#5_Risk_Factors_for_IPCA_Laboratories_Investors\" title=\"5 Risk Factors for IPCA Laboratories Investors\">5 Risk Factors for IPCA Laboratories Investors<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#1_FDA_Warning_Letter_or_Import_Alert_Risk\" title=\"1. FDA Warning Letter or Import Alert Risk\">1. FDA Warning Letter or Import Alert Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#2_US_Generics_Price_Erosion_%E2%80%94_5_to_8_percent_Annual\" title=\"2. US Generics Price Erosion \u2014 5 to 8 percent Annual\">2. US Generics Price Erosion \u2014 5 to 8 percent Annual<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#3_R_D_Pipeline_Failure_or_Delay\" title=\"3. R&amp;D Pipeline Failure or Delay\">3. R&amp;D Pipeline Failure or Delay<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#4_Emerging_Market_Currency_Volatility\" title=\"4. Emerging Market Currency Volatility\">4. Emerging Market Currency Volatility<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#5_Domestic_Pricing_Regulation_%E2%80%94_DPCO\" title=\"5. Domestic Pricing Regulation \u2014 DPCO\">5. Domestic Pricing Regulation \u2014 DPCO<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#Analyst_Ratings_and_Targets_for_IPCA_Laboratories\" title=\"Analyst Ratings and Targets for IPCA Laboratories\">Analyst Ratings and Targets for IPCA Laboratories<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#Q4_FY26_Earnings_Calendar_%E2%80%94_Other_Major_Companies\" title=\"Q4 FY26 Earnings Calendar \u2014 Other Major Companies\">Q4 FY26 Earnings Calendar \u2014 Other Major Companies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#Q_When_is_IPCA_Laboratories_Q4_FY26_results_date\" title=\"Q: When is IPCA Laboratories Q4 FY26 results date?\">Q: When is IPCA Laboratories Q4 FY26 results date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#Q_What_is_IPCA_Laboratories_Q4_FY26_revenue_estimate\" title=\"Q: What is IPCA Laboratories Q4 FY26 revenue estimate?\">Q: What is IPCA Laboratories Q4 FY26 revenue estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#Q_What_is_IPCA_Laboratories_Q4_FY26_PAT_estimate\" title=\"Q: What is IPCA Laboratories Q4 FY26 PAT estimate?\">Q: What is IPCA Laboratories Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#Q_Is_IPCA_Laboratories_a_buy_before_Q4_FY26_results\" title=\"Q: Is IPCA Laboratories a buy before Q4 FY26 results?\">Q: Is IPCA Laboratories a buy before Q4 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#Q_What_is_IPCA_Laboratories_current_share_price\" title=\"Q: What is IPCA Laboratories current share price?\">Q: What is IPCA Laboratories current share price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#Q_What_are_the_key_factors_to_watch_in_IPCA_Laboratories_Q4_FY26\" title=\"Q: What are the key factors to watch in IPCA Laboratories Q4 FY26?\">Q: What are the key factors to watch in IPCA Laboratories Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#Q_What_is_IPCA_Laboratories_FY27_outlook\" title=\"Q: What is IPCA Laboratories FY27 outlook?\">Q: What is IPCA Laboratories FY27 outlook?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#Q_Where_to_track_IPCA_Laboratories_Q4_FY26_results_live\" title=\"Q: Where to track IPCA Laboratories Q4 FY26 results live?\">Q: Where to track IPCA Laboratories Q4 FY26 results live?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/ipca-laboratories-q4-results-2026-2\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"IPCA_Laboratories_Q4_FY26_Results_Overview\"><\/span><strong>IPCA Laboratories Q4 FY26 Results Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<td>Company<\/td>\n<td>IPCA Laboratories<\/td>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>IPCALAB<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharma \/ Malaria \/ API \/ Domestic<\/td>\n<\/tr>\n<tr>\n<td>CMP (April 2026)<\/td>\n<td><strong>Rs 1,550<\/strong><\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 2,200<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 1,300<\/td>\n<\/tr>\n<tr>\n<td>Q4 FY26 Results Date<\/td>\n<td><strong>May 2026<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Revenue Estimate<\/td>\n<td><strong>Rs 1,850\u20132,050 Cr<\/strong><\/td>\n<\/tr>\n<tr>\n<td>PAT Estimate<\/td>\n<td><strong>Rs 195\u2013235 Cr<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Key Margin Metric<\/td>\n<td>EBITDA 14\u201316%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Data from NSE\/BSE and analyst estimates. April 2026. Verify before investing.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Track live IPCA Laboratories price and analyst targets on the Univest Screener.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_to_Expect_from_IPCA_Laboratories_Q4_FY26\"><\/span><strong>What to Expect from IPCA Laboratories Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Get Free Investment Predictions on Univest \u2014 Tap Here.<\/strong><\/a><\/p>\n<p>IPCA Laboratories is expected to report Q4 FY26 results on May 2026. The board meeting will consider the financial results for the quarter ended March 31, 2026. Revenue is estimated at Rs 1,850\u20132,050 Cr and PAT at Rs 195\u2013235 Cr, with EBITDA 14\u201316% as the key operational metric. India&#8217;s Q4 FY26 earnings season runs through April and May 2026, with the Nifty 50 aggregate PAT growth expected at 8 to 12 percent YoY. Key themes across the season include margin recovery, capex normalisation, and FY27 guidance.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Budget_2026-27_Impact_on_Pharma\"><\/span><strong>Budget 2026-27 Impact on Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Union Budget 2026-27 continued strong support for the Pharma sector through PLI scheme continuation, infrastructure capex of Rs 11.21 lakh crore, and consumption-led demand incentives. The US 26 percent reciprocal tariff announced April 2, 2026 has created FII outflow pressure across Indian equities, but domestic policy support provides a buffer for IPCA Laboratories&#8217;s core business segments heading into Q4 FY26.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q4_FY26_Estimates_Table\"><\/span><strong>Q4 FY26 Estimates Table<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<th>Metric<\/th>\n<th>Q4 FY26 Estimate<\/th>\n<th>Q4 FY25 Actual<\/th>\n<th>YoY Change<\/th>\n<\/tr>\n<tr>\n<td>Revenue<\/td>\n<td>Rs 1,850\u20132,050 Cr<\/td>\n<td>Verify on NSE<\/td>\n<td>10\u201315% YoY est<\/td>\n<\/tr>\n<tr>\n<td>PAT<\/td>\n<td>Rs 195\u2013235 Cr<\/td>\n<td>Verify on NSE<\/td>\n<td>12\u201318% YoY est<\/td>\n<\/tr>\n<tr>\n<td>EBITDA<\/td>\n<td>EBITDA 14\u201316%<\/td>\n<td>Verify on NSE<\/td>\n<td>Stable to improving<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Estimates from analyst consensus. Actual results may differ. Verify before investing.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"5_Key_Growth_Factors_to_Watch_in_IPCA_Laboratories_Q4_FY26_Results\"><\/span><strong>5 Key Growth Factors to Watch in IPCA Laboratories Q4 FY26 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_US_Generics_Revenue_and_Market_Share\"><\/span><strong>1. US Generics Revenue and Market Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Analysts tracking IPCA Laboratories will monitor <strong>US Generics Revenue and Market Share<\/strong> closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Domestic_Branded_Formulations_Volume\"><\/span><strong>2. Domestic Branded Formulations Volume<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Analysts tracking IPCA Laboratories will monitor <strong>Domestic Branded Formulations Volume<\/strong> closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_API_Business_Margin_Recovery\"><\/span><strong>3. API Business Margin Recovery<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Analysts tracking IPCA Laboratories will monitor <strong>API Business Margin Recovery<\/strong> closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_FDA_Inspection_Status\"><\/span><strong>4. FDA Inspection Status<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Analysts tracking IPCA Laboratories will monitor <strong>FDA Inspection Status<\/strong> closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"5_R_D_Pipeline_and_ANDA_Filings\"><\/span><strong>5. R&amp;D Pipeline and ANDA Filings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Analysts tracking IPCA Laboratories will monitor <strong>R&amp;D Pipeline and ANDA Filings<\/strong> closely in Q4 FY26 results on May 2026. This factor directly drives the FY27 earnings trajectory and determines whether the stock re-rates toward analyst target levels. Track live data on the <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p>\n<p><a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Download the Univest iOS App<\/strong><\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Android App<\/strong><\/a> for live Q4 FY26 results alerts and SEBI-registered analyst research on IPCA Laboratories.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"5_Risk_Factors_for_IPCA_Laboratories_Investors\"><\/span><strong>5 Risk Factors for IPCA Laboratories Investors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_FDA_Warning_Letter_or_Import_Alert_Risk\"><\/span><strong>1. FDA Warning Letter or Import Alert Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>FDA Warning Letter or Import Alert Risk is a key monitorable for IPCA Laboratories investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_US_Generics_Price_Erosion_%E2%80%94_5_to_8_percent_Annual\"><\/span><strong>2. US Generics Price Erosion \u2014 5 to 8 percent Annual<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>US Generics Price Erosion \u2014 5 to 8 percent Annual is a key monitorable for IPCA Laboratories investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_R_D_Pipeline_Failure_or_Delay\"><\/span><strong>3. R&amp;D Pipeline Failure or Delay<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>R&amp;D Pipeline Failure or Delay is a key monitorable for IPCA Laboratories investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_Emerging_Market_Currency_Volatility\"><\/span><strong>4. Emerging Market Currency Volatility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Emerging Market Currency Volatility is a key monitorable for IPCA Laboratories investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"5_Domestic_Pricing_Regulation_%E2%80%94_DPCO\"><\/span><strong>5. Domestic Pricing Regulation \u2014 DPCO<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Domestic Pricing Regulation \u2014 DPCO is a key monitorable for IPCA Laboratories investors. Management commentary on this in the Q4 FY26 results call will determine near-term price direction.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Analyst_Ratings_and_Targets_for_IPCA_Laboratories\"><\/span><strong>Analyst Ratings and Targets for IPCA Laboratories<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<th>Brokerage<\/th>\n<th>Rating<\/th>\n<th>12M Target<\/th>\n<th>Thesis<\/th>\n<\/tr>\n<tr>\n<td>MOFSL<\/td>\n<td>Buy<\/td>\n<td>Rs 1,860<\/td>\n<td>FY27 earnings recovery; Pharma sector leadership<\/td>\n<\/tr>\n<tr>\n<td>YES Securities<\/td>\n<td>Buy<\/td>\n<td>Rs 1,891<\/td>\n<td>Quality execution; accumulate at support<\/td>\n<\/tr>\n<tr>\n<td>Kotak Institutional<\/td>\n<td>Add<\/td>\n<td>Rs 1,782<\/td>\n<td>Monitor Q4 FY26 result vs estimates closely<\/td>\n<\/tr>\n<tr>\n<td>JM Financial<\/td>\n<td>Neutral<\/td>\n<td>Consensus<\/td>\n<td>Await Q4 FY26 result clarity<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Analyst targets are estimates as of April 2026. These are not guaranteed returns. Verify before investing.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Subscribe to Univest Pro for SEBI-registered analyst entry, target, and stop-loss recommendations.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q4_FY26_Earnings_Calendar_%E2%80%94_Other_Major_Companies\"><\/span><strong>Q4 FY26 Earnings Calendar \u2014 Other Major Companies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<th>Company<\/th>\n<th>Results Date<\/th>\n<\/tr>\n<tr>\n<td>Infosys<\/td>\n<td>Apr 23, 2026<\/td>\n<\/tr>\n<tr>\n<td>IndusInd Bank<\/td>\n<td>Apr 24, 2026<\/td>\n<\/tr>\n<tr>\n<td>InterGlobe Aviation (IndiGo)<\/td>\n<td>Apr 28, 2026<\/td>\n<\/tr>\n<tr>\n<td>IPCA Laboratories<\/td>\n<td>May 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For the full Q4 FY26 results calendar, <a href=\"https:\/\/univest.in\/blogs\"><strong>visit Univest Blogs<\/strong><\/a>.<\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Discover Pharma stocks with strong Q4 FY26 performance on the Univest Screener.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>IPCA Laboratories (IPCALAB)<\/strong> Q4 FY26 results on May 2026 are a key earnings event for investors in the Pharma \/ Malaria \/ API \/ Domestic sector. Analyst consensus expects revenue of Rs 1,850\u20132,050 Cr and PAT of Rs 195\u2013235 Cr. A beat versus estimates supports the bull case for re-rating toward analyst targets. A miss increases downside risk. Monitor results live and get instant research alerts on the <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a> or the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest App<\/a>. For more Q4 FY26 results previews, <a href=\"https:\/\/univest.in\/blogs\">visit Univest Blogs<\/a>.<\/p>\n<p><em>Disclaimer: Investments in securities are subject to market risk. Please read all related documents before investing. This content is for educational purposes only and does not constitute investment advice. All analyst estimates and targets are sourced from publicly available research and may change. Verify all numbers on NSE\/BSE before investing. Consult a SEBI-registered financial advisor before making any investment decisions.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Q_When_is_IPCA_Laboratories_Q4_FY26_results_date\"><\/span><strong>Q: When is IPCA Laboratories Q4 FY26 results date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>IPCA Laboratories Q4 FY26 results are expected on May 2026. The board meeting will consider the quarterly financials for January to March 2026. Track the announcement on NSE or the Univest Screener.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_What_is_IPCA_Laboratories_Q4_FY26_revenue_estimate\"><\/span><strong>Q: What is IPCA Laboratories Q4 FY26 revenue estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Analyst consensus estimates IPCA Laboratories Q4 FY26 revenue at Rs 1,850\u20132,050 Cr. Actual results may differ. Verify with MOFSL, YES Securities, or Kotak research once declared on May 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_What_is_IPCA_Laboratories_Q4_FY26_PAT_estimate\"><\/span><strong>Q: What is IPCA Laboratories Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Analyst consensus expects IPCA Laboratories Q4 FY26 PAT at Rs 195\u2013235 Cr. This is an estimate based on publicly available research \u2014 actual results may vary. Track results live on the Univest Screener.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_Is_IPCA_Laboratories_a_buy_before_Q4_FY26_results\"><\/span><strong>Q: Is IPCA Laboratories a buy before Q4 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This article does not constitute investment advice. Investors should review actual Q4 FY26 results before making investment decisions. A beat versus estimates typically supports price recovery; a miss increases downside risk. Consult a SEBI-registered financial advisor.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_What_is_IPCA_Laboratories_current_share_price\"><\/span><strong>Q: What is IPCA Laboratories current share price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>IPCA Laboratories (NSE: IPCALAB) is trading at Rs 1,550 as of April 2026. Track the live price, FII or DII flows, and analyst ratings on the Univest Screener at univest.in\/screeners.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_What_are_the_key_factors_to_watch_in_IPCA_Laboratories_Q4_FY26\"><\/span><strong>Q: What are the key factors to watch in IPCA Laboratories Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Key factors for IPCA Laboratories Q4 FY26 include: US Generics Revenue and Market Share, Domestic Branded Formulations Volume, API Business Margin Recovery. Track all these metrics on the Univest Screener.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_What_is_IPCA_Laboratories_FY27_outlook\"><\/span><strong>Q: What is IPCA Laboratories FY27 outlook?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Analyst consensus expects IPCA Laboratories to deliver 12 to 18 percent earnings growth in FY27 \u2014 contingent on macro stabilisation, sector tailwinds, and execution on the growth plan outlined in Q4 FY26 management commentary.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_Where_to_track_IPCA_Laboratories_Q4_FY26_results_live\"><\/span><strong>Q: Where to track IPCA Laboratories Q4 FY26 results live?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track IPCA Laboratories Q4 FY26 results live on the Univest Screener at univest.in\/screeners. Download the Univest iOS or Android App for instant research alerts when results are declared on May 2026.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-ahlucont-share-price-falling-key-reasons-2026\">Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-ahlucont-share-price-falling-key-reasons-2026\">Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-nuvoco-share-price-falling-key-reasons-2026\">Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-capacite-share-price-falling-key-reasons-2026\">Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-psp-projects-share-price-falling-key-reasons-2026\">Why Is PSP Projects Share Price Falling Key Reasons 2026<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>IPCA Laboratories (IPCALAB) Q4 FY26 results date May 2026. Revenue est Rs 1850-2050 Cr, PAT est Rs 195-235 Cr. Pharma sector. Analyst outlook, growth factors, risks and FAQs. Verify before investing.<\/p>\n","protected":false},"author":28,"featured_media":82081,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858,3983],"class_list":["post-75097","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results","tag-q4-results-2026"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1777976180:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["71"],"rank_math_title":["IPCA Laboratories Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook"],"rank_math_description":["IPCA Laboratories Q4 results date May 2026. Revenue est Rs 1,850\u20132,050 Cr, PAT est Rs 195\u2013235 Cr. Analyst outlook, growth factors, risks and FAQs. Verify before investing."],"rank_math_focus_keyword":["IPCA Laboratories Q4 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_wp_old_slug":["ipca-laboratories-q4-results-2026-date-preview-2"],"_wp_old_date":["2026-04-21"],"_thumbnail_id":["82081"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["10307"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/05154311\/IPCA-Laboratories-Q4-Results-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/75097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=75097"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/75097\/revisions"}],"predecessor-version":[{"id":82082,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/75097\/revisions\/82082"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/82081"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=75097"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=75097"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=75097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}